LOG IN
SIGN UP
MARKET
VYGR
VYGR
Voyager Therapeutics Inc
NASDAQ
5.92
-0.09
-1.50%
After Hours: 5.92 0 0.00% 16:49 09/30 EDT
OPEN
5.94
PREV CLOSE
6.01
HIGH
6.08
LOW
5.81
VOLUME
172.35K
TURNOVER
0
52 WEEK HIGH
10.60
52 WEEK LOW
2.460
MARKET CAP
228.79M
P/E (TTM)
-3.7635
1D
5D
1M
3M
1Y
5Y
Voyager Therapeutics to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today announced that manag...
GlobeNewswire · 5d ago
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, has entered into employmen...
GlobeNewswire · 09/22 20:01
Voyager Therapeutics hires new finance chief
Peter Pfreundschuh has been appointed as CFO of Voyager Therapeutics (NASDAQ:<a href="https://seekingalpha.com/symbol/VYGR?utm_medium=referral&utm_source=webull.com" title="Voyager Therapeutics, Inc." target="_bl...
Seekingalpha · 09/07 11:55
Voyager Therapeutics Names Peter Pfreundschuh Finance Chief
Voyager Therapeutics Names Peter Pfreundschuh Finance Chief
MT Newswires · 09/07 08:50
Voyager Therapeutics Prioritizes Pipeline With Cash Runway Into 2024
Benzinga · 08/05 15:14
Voyager Therapeutics (VYGR) Reports Q2 Loss, Misses Revenue Estimates
Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 10.71% and 71.52%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/04 21:15
Voyager Therapeutics GAAP EPS of -$0.50 misses by $0.02
Voyager Therapeutics press release (<span class="t...
Seekingalpha · 08/04 21:14
-- Earnings Flash (VYGR) VOYAGER THERAPEUTICS Reports Q2 Loss $-0.50
-- Earnings Flash (VYGR) VOYAGER THERAPEUTICS Reports Q2 Loss $-0.50
MT Newswires · 08/04 16:18
About VYGR
Voyager Therapeutics, Inc. is a gene therapy company, which is focused on developing treatments and platform technologies. Its gene therapy platforms enable it to engineer, optimize, manufacture, and deliver its adeno-associated virus (AAV)-based gene therapies. It is identifying AAV capsids, the outer viral protein shells that enclose genetic material of a virus payload. It has developed a AAV capsid discovery platform, Tropism Redirection of AAV by Cell Type-Specific Expression of RNA (TRACER) to facilitate the selection of AAV capsids with blood brain barrier (BBB) crossing and cell-specific transduction properties for therapeutic applications. Its gene therapy programs include treatment programs for Huntington's disease, monogenic amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), and various diseases linked to GBA1 mutations, including Parkinson's disease, Lewy body dementia and Gaucher's disease. It also focuses on tauopathies and indications in neuro-oncology.
Webull offers kinds of Voyager Therapeutics Inc stock information, including NASDAQ:VYGR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VYGR stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading VYGR stock methods without spending real money on the virtual paper trading platform.